The lab, which is currently available to customers, can handle highly potent compounds.
CordenPharma announced on Oct. 19, 2020 that it has completed the construction of its highly potent API laboratory in its Boulder, CO facility.
The lab, which is currently available to customers, can handle highly potent compounds with an OEL as low as 1 ng/m3, according to a company press release.
“Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, director of CordenPharma’s Global Highly Potent & Oncology Platform, in the press release.
Source: CordenPharma
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.